The return of two old targets?

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 6, 2006, Pages 785-788

  Suckling, Keith E ^a  

^a NONE   (United Kingdom)

Author keywords

Acyl CoA:cholesterol acyltransferase; Atherosclerosis; Squalene synthase inhibitor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AVASIMIBE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PACTIMIBE; PHOSPHOLIPASE A; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; TAK 475; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADRENAL DISEASE; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVASCULAR ULTRASOUND; MOLECULAR CLONING; NONHUMAN; PREDICTION; PROTEIN FUNCTION;

ATHEROSCLEROSIS; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; STEROL O-ACYLTRANSFERASE;

EID: 37849187005     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.6.785     Document Type: Editorial

References (29)

1. SHEIKINE Y, HANSSON GK: Chemokines and atherosclerosis. Ann. Med. (2004) 36:98-118.
2. TOTH PP, DAVIDSON MH: Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (2005) 6:131-139.
3. SCHAEFER EJ, ASZTALOS BF: Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr. Opin. Lipidol. (2006) 17:394-398.
4. KEARNEY PM, BAIGENT C: Statins: are ny questions unanswered? Curr. Opin. Lipidol. (2006) 17:418-425.
5. BUHMAN KF, ACCAD M, FARESE RV: Mammalian acyl-CoA: cholesterol acyltransferases. Biochim. Biophys. Acta (2000) 1529:142-154.
6. TANSEY TR, SHECHTER I: Structure and regulation of mammalian squalene synthase. Biochim. Biophys. Acta (2000) 1529:49-62.
7. SUCKLING KE, STANGE EF: Role of acyl-CoA: cholesterol acyltransferase in cellular cholesterol metabolism. J. Lipid Res. (1985) 26:647-671.
8. HARTE RA, YEAMAN SJ, JACKSON B, SUCKLING KE: Effect of membrane environment on inhibition of acyl-CoA:cholesterol acyltransferase by a range of synthetic inhibitors. Biochim. Biophys. Acta (1995) 1258:241-250.
9. MACPHEE CH, NELSON JJ, ZALEWSKI A: Lipoprotein associated phospholipase A(2) as a target of therapy. Curr. Opin. Lipidol. (2005) 16:442-446.
10. CHANG CC, HUH HY, CADIGAN KM, CHANG TY: Molecular cloning and funcational expression of human acylcoenzyme-acholesterol acyltransferase cdna in mutant chinese hamster ovary cells. J. Biol. Chem (1993) 268(28):70747-70455.
11. CHANG TY, CHANG CCY, LIN S, YU CJ, LI BL, MIYAZAKI A: Roles of acyl-coenzyme A: cholesterol acyltransferase-1 and-2. Curr. Opin. Lipidol. (2001) 12:289-296.
12. BOCAN TMA, KRAUSE BR, ROSEBURY WS et al.: The ACAT inhibitor avasimibe reduces macrophages; and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. (2000) 20:70-79.
13. DELSING DJM, OFFERMAN EH, VAN DUYVENVOORDE W et al.: Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation (2001) 103:1778-1786.
14. BURNETT JR, WILCOX LJ, TELFORD DE et al.: Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J. Lipid Res. (1999) 40:1317-1327.
15. ROBERTSON DG, BREIDER MA, MILAD MA: Preclinical safety evaluation of avasimibe in beagle dogs: an ACAT inhibitor with minimal adrenal effects. Toxicol. Sci. (2001) 59:324-334.
16. INSULL W, KOREN M, DAVIGNON J et al.: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 157:137-144.
17. TARDIF JC, GREGOIRE J, L'ALLIER PL et al.: Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation (2004) 110:3372-3377.
18. NICHOLLS SJ, SIPAHI I, SCHOENHAGEN P, CROWE T, TUZCU EM, NISSEN SE: Application of intravascular ultrasound in anti-atherosclerotic drug development. Nat. Rev. Drug Discov. (2006) 5:485-492.
19. KITAYAMA K, TANIMOTO T, KOGA T, TERASAKA N, FUJIOKA T, INABA T: Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe. Eur. J. Pharmacol. (2006) 540:121-130.
20. KITAYAMA K, KOGA T, INABA T, FUJIOKA T: Multiple mechanisms of hypocholesterolemic action of pactimibe, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor. Eur. J. Pharmacol. (2006) 543:123-132.
21. KITAYAMA K, KOGA T, MAEDA N, INABA T, FUJIOKA T: Pacrimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits. Eur. J. Pharmacol. (2006) 539:81-88.
22. TERASAKA N, MIYAZAKI A, KASANUKI N et al: ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice. Atherosclerosis (2006) (Epub ahead of print).
23. NISSEN SE, TUZCU EM, BREWER HB et al., the ACAT In travascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators: Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. (2006) 354:1253-1263.
24. BELL TA III, BROWN JM, GRAHAM MJ, LEMONIDIS KM, CROOKE RM, RUDEL LL: Liver-specific inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B 100-only low-density lipoprotein receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. (2006) 26:1814-1820.
25. VAIDYA S, BOSTEDOR R, KURTZ MM, BERGSTROM JD, BANSAL VS: Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. Arch. Biochem. Biophys. (1998) 355:84-92.
26. WILLIAMS SJ, BEST JD: Novel microsomal triglyceride transfer protein inhibitors. Expert Opin. Ther. Patents (2003) 13:479-488.
27. AMANO Y, NISHIMOTO T, TOZAWA R, ISHIKAWA E, IMURA Y, SUGIYAMA Y: Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur. J. Pharmacol. (2003) 466:155-161.
28. NISHIMOTO T, AMANO Y, TOZAWA R et al.: Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br. J. Pharmacol. (2003) 139:911-918.
29. SHIOMI M, YAMADA S, AMANO Y, NISHIMOTO T, ITO T: Sabilization of coronary atherosclerosis by a squalene synthase inhibitor. Atherosclerosis (2006) 7:339.